The Novartis Commitment to Patients and Caregivers

Only by working together and delivering on the four pillars of our Commitment, can we improve outcomes for patients and change the practice of medicine.

Our Commitment is based on four pillars

- Respecting and understanding the patient community perspective
- Conducting responsible clinical trials
- Expanding access to our medicines
- Recognizing the importance of transparency and reporting

Sharing our fifth year of progress

- **87%** EARLY RESEARCH PROGRAMS in general medicines obtained patient insights before first-in-human trials (healthy volunteers).
- **74** CLINICAL DEVELOPMENT PROGRAMS comprising 85 clinical trials, had a patient engagement component to obtain the patient perspective on the design and/or conduct of clinical trials.
- **191** SIMPLIFIED SUMMARIES from Phase 1 - 4 clinical trials sent to investigators to share with 35 500 trial participants and posted on novartis.com/clinicaltrials.
- **202** CLINICAL TRIALS included Patient Reported Outcomes (PRO) conducted in 77 countries.
- **7302** PATIENTS REACHED THROUGH MANAGED ACCESS PROGRAMS in 80 countries providing access to locally unlicensed Novartis medicines. At the end of 2022, more than 9 700 patients were receiving treatment through MAPs.
- **54.6 m** PATIENTS REACHED through access programs, predominantly in low- and middle-income countries (LMICs).

---

1. 2022 data
2. Patient engagement component defined as interaction with patients to seek input, advice or guidance.
5. Includes patients reached with medicines through Novartis Global Health, as well as patients reached with support programs, emerging market brands and donations. www.novartis.com/reportingsuite.
415 patients participated in three studies completed in 2022 to inform decisions on the type of devices, technology or services. 3 APPs that help reduce the burden of treatment and trial participation have been developed in a co-creation setting before being included in trials.

Trial feedback questionnaires from 22 new clinical trials sent to patients to obtain insights on their participation experience; 1600 new patient responses were received from 50 countries.

248 clinical trials listed for secure, voluntary data-sharing on ClinicalStudyDataRequest.com (CSDR).

11 clinical trials set up to pilot return of individual results to trial participants (IRR) once the clinical trial report is publicly available.

158 patient organizations in 62 disease areas from 28 countries engaged in global initiatives to inform decision-making. The Asia Pacific, Middle East and Africa Summit (APPIS) brought together 2,000 external attendees, representing more than 300 patient organizations from 46 countries including China and Japan.

#6 ranking in Corporate Reputation – evaluated by over 1,359 patient organizations.

#1 reputation ranking for Multiple Sclerosis.

#2 reputation ranking for Neurological disorders.

#3 reputation ranking for Autoimmune disease and Cancer.

Expanding access to our medicines

#4 in Access to Medicines Index – assessing companies’ performance in providing access to medicines for patients.

1 bn antimalarial treatments delivered to patients since 1999, with more than 90% supplied without profit.

In 2022, we continued to expand our emerging market brands (EMB) program, adding 29 new EMBs including for Leqvio®, Piqray® and Kesimpta®.

Pledged USD 250 million over five years (2021-2025) to advance new treatments for neglected tropical diseases and malaria.

In 2022, Novartis became the first pharmaceutical company to grant a freedom to operate license to an innovative treatment for chronic myeloid leukemia to the new Access to Oncology Medicines (ATOM) coalition.

2,969 clinical trials posted on novartiscclinicaltrials.com, sharing results of clinical trials with society.

Returning to society with 27 manuscripts and 46 posters/oral presentations published on insights obtained from the patient community, to share the learnings.

 Reported engagement with and support for 1,348 patient organizations in 78 countries in Transfer of Value report.